Jon Scherrer, M.S.
Lab Head
Jon Scherrer, M.S., has over 25 years of experience in biopharma and startup companies, spanning drug-target discovery, high-throughput screening campaigns, and preclinical studies to develop small-molecule, protein-biologic, and nucleic acid-based pharmaceuticals. These efforts contributed to the growth of three startup companies, Ribozyme Pharmaceuticals, ADRx, and Capsida Biotherapeutics, with successful product launches during 18 years at Amgen, Inc. In these capacities, he has published using nucleic acid and lipid conjugates for improved drug delivery and mechanism of action studies for small-molecule therapeutics, targeting rheumatoid arthritis, osteoporosis, and parathyroid disease. The current focus has been on addressing unmet medical needs in treating Alzheimer’s and Parkinson’s disease. He has contributed to publications demonstrating the use of next-generation synthetic AAVs to deliver amyloid reduction therapies and the use of human neurons for AAV-based gene therapy potency assays.